Vectus Biosystems Ltd
VBS
Company Profile
Business description
Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company has developed and patented various novel compounds for the treatment of chronic fibrosis, including heart, kidney, liver, and lung fibrosis. Its drug candidate VB0004, is aimed at inhibiting and reversing the loss of functional tissue due to fibrosis, is in its human trials phase.
Contact
26-34 Dunning Avenue
Unit 5, Ground Floor
Rosebery
SydneyNSW2018
AUST: +61 283441300
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
Stocks News & Analysis
stocks
AI isn’t an economic moat killer, but it will disrupt industries
How we’re rethinking companies’ competitive advantages in an AI-first world.
stocks
AI lands a blow on some Aussie stocks – yet stands to benefit others
AI is reshaping ASX tech moats - but some are more insulated than others.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,571.30 | 125.30 | -1.44% |
| CAC 40 | 7,743.92 | 17.72 | 0.23% |
| DAX 40 | 22,636.91 | 16.95 | -0.07% |
| Dow JONES (US) | 46,300.23 | 91.76 | 0.20% |
| FTSE 100 | 9,965.16 | 71.01 | 0.72% |
| HKSE | 25,063.71 | 681.24 | 2.79% |
| NASDAQ | 21,842.29 | 104.47 | -0.48% |
| Nikkei 225 | 52,252.28 | 736.79 | 1.43% |
| NZX 50 Index | 12,701.75 | 288.24 | -2.22% |
| S&P 500 | 6,578.71 | 2.29 | -0.03% |
| S&P/ASX 200 | 8,379.40 | 125.20 | -1.47% |
| SSE Composite Index | 3,881.28 | 68.00 | 1.78% |